Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | MPL | P40238 | 3/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.31 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.31 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4445323 | 0.84 | ADRA1D (0.44) | PDE7AADRA1DADRA1AADRA1BHDAC4 | |
| SCHEMBL16729399 | 0.82 | HDAC6 (0.38) | PDE7AADRA1DADRA1AADRA1BHDAC4 | |
| SCHEMBL3868254 | 0.79 | HDAC4 (0.42) | PDE7AHDAC4BDKRB1 | |
| SCHEMBL625570 | 0.78 | HDAC4 (0.45) | PDE7AADRA1DADRA1AADRA1BHDAC4 | |
| SCHEMBL9818617 | 0.78 | HDAC4 (0.49) | PDE7AADRA1DADRA1AADRA1BHDAC4 | |
| SCHEMBL30183839 | 0.76 | PDE7A (0.31) | PDE7AHDAC4BDKRB1 | |
| SCHEMBL21805029 | 0.76 | PDE7A (0.31) | PDE7AHDAC4BDKRB1 | |
| SCHEMBL30251132 | 0.76 | BDKRB1 (0.33) | HDAC4BDKRB1PDK2 | |
| SCHEMBL5726943 | 0.74 | ADRA1D (0.41) | PDE7AADRA1DADRA1AADRA1BHDAC4 | |
| SCHEMBL23778356 | 0.73 | ADRA1D (0.42) | PDE7AADRA1DADRA1AADRA1BHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388006-B2 | Non-steroidal progesting | BAYER SCHERING PHARMA AG (DE) | 2008-06-17 | — | — | US | disclosed |
| EP-1482925-B1 | 5-(2-HYDROXY-3-'1-(3-TRIFLUOROMETHYLPHENYL)-CYCLOPROPL]-PROPIONYLAMINO)-PHTALIDE AND RELATED COMPOUNDS WITH PROGESTERONE RECEPTOR MODULATING ACTIVITY FOR USE IN FERTILITY CONTROL AND HORMONE REPLACEMENT THERAPY | SCHERING AG (DE) | 2007-01-17 | — | — | EP | disclosed |
| EP-1482925-A1 | 5-(2-HYDROXY-3-'1-(3-TRIFLUOROMETHYLPHENYL)-CYCLOPROPL!-PROPIONYLAMINO)-PHTALIDE AND RELATED COMPOUNDS WITH PROGESTERONE RECEPTOR MODULATING ACTIVITY FOR USE IN FERTILITY CONTROL AND HORMONE REPLACEMENT THERAPY | Schering AG (DE) | 2004-12-08 | — | — | EP | disclosed |
| US-20030232824-A1 | Non-steroidal progesting | SCHERING AG (DE) | 2003-12-18 | — | — | US | disclosed |
| WO-2003075915-A1 | 5-}2-HYDROXY-3-`1-(3-TRIFLUOROMETHYLPHENYL)-CYCLOPROPYL!-PROPIONYLAMINO}- PHTALIDE AND RELATED COMPOUNDS WITH PROGESTERONE RECEPTOR MODULATING ACTIVITY FOR USE IN FERTILITY CONTROL AND HORMONE REPLACEMENT THERAPY | SCHERING AG (DE) | 2003-09-18 | — | — | WO | disclosed |
| EP-1344776-A1 | 5- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -phtalide and 6- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -4-methyl-2,3-benzoxazin-1-one derivatives with progesterone receptor modulating activity for use in fertility control, hormone replacement therapy and the treatment of gynecological disorders | Schering Aktiengesellschaft (DE) | 2003-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232824-A1 | Non-steroidal progesting | PGR, NR5A1, GPER1 | PDE7A 3021/4885ADRA1D 166/4885ADRA1A 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.